Current Status of Dyslipidemia Treatment for Stroke Prevention

被引：17
作者：
Aradine, Elizabeth [1 ,2 ]
Hou, Yan [1 ,2 ]
Cronin, Carolyn A. [1 ,2 ]
Chaturvedi, Seemant [1 ,2 ]
机构：
[1] Univ Maryland, Sch Med, Stroke Div, 110 S Paca St, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Neurol, 110 S Paca St, Baltimore, MD 21201 USA
来源：
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS | 2020年 / 20卷 / 08期
关键词：
Cholesterol; Stroke; Statins; Triglycerides; Low-density lipoprotein; HIGH-DOSE ATORVASTATIN; THERAPY; PRAVASTATIN; ATHEROSCLEROSIS; CHOLESTEROL; PROGRESSION; REDUCTION; EZETIMIBE; EFFICACY; DISEASE;
D O I：
10.1007/s11910-020-01052-4
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Purpose of Review Elevated cholesterol is an established risk factor for ischemic stroke. The value of statins for stroke prevention has been clear for more than a decade. Recent Findings However, the use of new medication combinations such as ezetimibe or proprotein convertase subtilisin-kexin type 9 inhibitors plus statins is increasing and the value for reducing stroke has been shown for these combination therapies. Recent data also support the strategy of lowering triglycerides for stroke prevention. A modern approach to dyslipidemia treatment and its relation to stroke prevention is summarized in this paper.
引用
收藏
页数：8
相关论文
共 33 条
  • [1] Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study
    Albert, MA
    Danielson, E
    Rifai, N
    Ridker, PM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01): : 64 - 70
  • [2] A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
    Amarenco, P.
    Kim, J. S.
    Labreuche, J.
    Charles, H.
    Abtan, J.
    Bejot, Y.
    Cabrejo, L.
    Cha, J-K
    Ducrocq, G.
    Giroud, M.
    Guidoux, C.
    Hobeanu, C.
    Kim, Y. J.
    Lapergue, B.
    Lavallee, P. C.
    Lee, B-C
    Lee, K-B
    Leys, D.
    Mahagne, M-H
    Meseguer, E.
    Nighoghossian, N.
    Pico, F.
    Samson, Y.
    Sibon, I
    Steg, P. G.
    Sung, S-M
    Touboul, P. J.
    Touze, E.
    Varenne, O.
    Vicaut, E.
    Yelles, N.
    Bruckert, E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01) : 9 - 19
  • [3] Amarenco P, 2006, NEW ENGL J MED, V355, P549
  • [4] Amarin Pharmaceuticals Ireland Ltd, VASCEPA IC ETH CAPS
  • [5] Amgen Inc, REPATHA EV INJ SUBC
  • [6] [Anonymous], 2001, MERCK SCHER PLOUGH P
  • [7] [Anonymous], PRALUENT AL INJ SUBC
  • [8] Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
    Bhatt, Deepak L.
    Steg, P. Gabriel
    Miller, Michael
    Brinton, Eliot A.
    Jacobson, Terry A.
    Ketchum, Steven B.
    Doyle, Ralph T., Jr.
    Juliano, Rebecca A.
    Jiao, Lixia
    Granowitz, Craig
    Tardif, Jean-Claude
    Ballantyne, Christie M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (01) : 11 - 22
  • [9] Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
    Bohula, Erin A.
    Wiviott, Stephen D.
    Giugliano, Robert P.
    Blazing, Michael A.
    Park, Jeong-Gun
    Murphy, Sabina A.
    White, Jennifer A.
    Mach, Francois
    Van de Werf, Frans
    Dalby, Anthony J.
    White, Harvey D.
    Tershakovec, Andrew M.
    Cannon, Christopher P.
    Braunwald, Eugene
    [J]. CIRCULATION, 2017, 136 (25) : 2440 - +
  • [10] The effects of statin therapy on carotid plaque composition and volume: A systematic review and meta-analysis
    Brinjikji, Waleed
    Lehman, Vance T.
    Kallmes, David F.
    Rabinstein, Alejandro A.
    Lanzino, Giuseppe
    Murad, Mohammad H.
    Mulvagh, Sharon
    Klaas, James
    Graff-Radford, Jonathan
    DeMarco, Kevin J.
    Huston, John, III
    [J]. JOURNAL OF NEURORADIOLOGY, 2017, 44 (04) : 234 - 240
1234